CGRP Receptor Antagonism in COVID-19: Potential Cardiopulmonary Adverse Effects

Recently, the US FDA has authorized a drug repurposing trial with calcitonin gene-related peptide (CGRP) receptor antagonists to reduce lung inflammation in coronavirus 2019 (COVID-19). However, the well-established cardiopulmonary protective effects of CGRP raise concerns about the safety of antagonizing CGRP in COVID-19. Awareness regarding potential cardiopulmonary adverse effects may enable their early detection and prevent illness from worsening.

Automated summary

The US FDA has authorized a drug repurposing trial using CGRP receptor antagonists to reduce lung inflammation in COVID-19. However, concerns about potential cardiopulmonary adverse effects of antagonizing CGRP have been raised, highlighting the importance of early detection and prevention.